<SEC-DOCUMENT>0001104659-13-068246.txt : 20131017
<SEC-HEADER>0001104659-13-068246.hdr.sgml : 20131017
<ACCEPTANCE-DATETIME>20130905170417
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-13-068246
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20130905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AASTROM BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000887359
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943096597
		STATE OF INCORPORATION:			MI
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		24 FRANKL LLOYD WRIGHT DR
		STREET 2:		PO BOX 376
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48106
		BUSINESS PHONE:		7349305555
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="98%" style="border-collapse:collapse;width:98.4%;">
<tr height="102" style="height:76.65pt;">
<td width="41%" height="102" valign="top" style="height:76.65pt;padding:0in 0in 0in 0in;width:41.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="254" height="33" src="g191914bgi001.jpg" alt="GRAPHIC"></font></p>    </td>
<td width="37%" height="102" valign="top" style="height:76.65pt;padding:0in 0in 0in 0in;width:37.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" height="102" valign="top" style="height:76.65pt;padding:0in 0in 0in 0in;width:20.96%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Goodwin   Procter LLP<br>   Counselors at Law</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exchange Place<br>   Boston, MA 02109</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: 617.570.1000</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">F:   617.523.1231</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 2.0in .0001pt 0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">September&nbsp;5, 2013</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">VIA EDGAR AND FEDERAL EXPRESS</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">United States Securities and Exchange Commission<br> Division of Corporation Finance<br> Mail Stop 4561<br> 100 F Street, N.E.<br> Washington, D.C. 20549<br> Attention:&#160; Jeffrey P. Riedler</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Aastrom Biosciences,&nbsp;Inc.<br> Preliminary Proxy Statement on Schedule 14A<br> Filed August&nbsp;26, 2013<br>  </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">File No.&nbsp;001-35280</font></b></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Mr.&nbsp;Riedler:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This letter is submitted on behalf of Aastrom Biosciences,&nbsp;Inc. (the &#147;<b>Company</b>&#148;) in response to the comment of the staff of the Division of Corporation Finance (the &#147;<b>Staff</b>&#148;) of the U.S.&nbsp;Securities and Exchange Commission (the &#147;<b>Commission</b>&#148;) with respect to the Company&#146;s Preliminary Proxy Statement on Schedule 14A, filed on August&nbsp;26, 2013 (the &#147;<b>Preliminary Proxy Statement</b>&#148;), as set forth in your letter dated August&nbsp;30, 2013 addressed to Dominick Colangelo, President, Chief Executive Officer and Director of the Company (the &#147;<b>Comment Letter</b>&#148;).&#160; The Company is concurrently filing the Company&#146;s Definitive Proxy Statement on Schedule 14A (the &#147;<b>Definitive Proxy Statement</b>&#148;), which includes changes to reflect responses to the Staff&#146;s comments.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For reference purposes, the text of the Comment Letter has been reproduced herein with responses below the numbered comment.&#160; For your convenience, we have italicized the reproduced Staff comment from the Comment Letter.&#160; Unless otherwise indicated, page&nbsp;references in the descriptions of the Staff&#146;s comment refer to the Preliminary Proxy Statement, and page&nbsp;references in the responses refer to the Definitive Proxy Statement.&#160; All capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Definitive Proxy Statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The responses provided herein are based upon information provided to Goodwin Procter LLP by the Company.&#160; In addition to submitting this letter via EDGAR, we are sending via courier two (2)&nbsp;copies of each of this letter and the Definitive Proxy Statement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107899\13-19191-4\task6238406\19191-4-bg.htm',USER='107899',CD='Sep  6 02:15 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proposal No.&nbsp;1 &#151; Proposal to Amend the Articles &#133;., page&nbsp;4</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">1.</font></i><i><font size="1" style="font-size:3.0pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></i><i><font size="2" style="font-size:10.0pt;font-style:italic;">Please disclose whether you currently have, or do not have, any plans with respect to the potential increased number of authorized shares available for issuance. If such plans exist, please disclose all material information.</font></i></p>
<p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">RESPONSE:&#160; In response to the Staff&#146;s comment, the Company has added additional disclosure on page&nbsp;5 of the Definitive Proxy Statement clarifying that the Company does not have any plans with respect to the potential increased number of authorized shares.</font></p>
<p style="margin:0in 0in .0001pt 1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*&#160;&#160;&#160;&#160; *&#160;&#160;&#160;&#160; *</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_021448_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\107899\13-19191-4\task6238406\19191-4-bg.htm',USER='107899',CD='Sep  6 02:15 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If you should have any questions concerning the enclosed matters, please contact the undersigned at (617) 570-1055.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sincerely,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Mitchell S. Bloom</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mitchell   S. Bloom,&nbsp;Esq.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 3.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Enclosures</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Dominick C. Colangelo, President&nbsp;&amp; Chief Executive Officer, <i>Aastrom Biosciences,&nbsp;Inc..<br>  </i>Michael Elliston, &#160;Controller and Principal Accounting Officer, <i>Aastrom Biosciences,&nbsp;Inc.<br>  </i>Danielle Lauzon,&nbsp;Esq., <i>Goodwin Procter LLP<br>  </i>Douglas S. Parker,&nbsp;Esq., <i>Dykema Gossett PLLC</i></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_021523_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\107899\13-19191-4\task6238406\19191-4-bg.htm',USER='107899',CD='Sep  6 02:15 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g191914bgi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g191914bgi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MP``+"``A`/X!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/9J**************\]^-W_`"3YO^ON+^M:_P`,/^2<
M:-_UQ/\`Z&U=7111111111111117&6NM^(/%MQ<OX?EM=-TRUF:`7=Q"9GN'
M4\E%R`%]SUK;T*;7]]Q:Z[;V[-#M,5Y;'"3@_P"P22I'?MSQ57Q!KFH0ZI::
M%H<,,FI7:-*TMQGR[>)3@NP')))P!5"YU3Q+X5D@N=<N;/4]+EE6*::"`PR6
MQ8X5B,D,N2`>XS6MXFUV71;:VBLK876HW\PM[2%FVJ7()+,>R@`DUDWL_C70
M;-]6NKK3M5@@7S+FSAMFB<(.6,;;CD@<X(YQ71G48Y]#.IV;!XWMO/B8C@@K
MN%<OHUQXZU;0K/5HM2T8_:H5F$$EI(HY&=I8/^N*WO#>NG7;&5I[8VE[:3-;
MW=N6W>7(O7![@@@@^AJA:>*)(-*UZ;51&MQHLTJN$!`=,;XSCW4@?6J>F^,[
MQO`5]J^IVZ1:I8;XIK=1@>=_`,9[[D_.NKL?M/V"W-Z4-SY2^=L&%WXYP/3-
M9?@[5[K7/#5OJ%YL\Z1Y`WEC`^61E''T`K*T3QK)<>*=1T35(1"JWLD%A<@8
M28J`3&3_`'P"#[CZ5JZ1JMU>^)=>L)BGD6#P+#A<$!H]QR>_-<S\;O\`DGS?
M]?<7]:U_AA_R3C1O^N)_]#:EUO4->E\76^B:/>6EHC6+7+O<6YE)(<+@88>M
M1)JOB+1?$>EZ=J]W8:A#JC/&IMX&BDB95+9P6.5XP?3BKWC#5-2TVTT]-+EA
MBN+V_BM?,FC+JH;/.`1Z>M9.MW_B_P`+Z7)K%YJFE7UO;E3);BU:%I%)`PK;
MS\W/'%=5J>J6^DZ/<ZI=;E@MH3*XQS@#./KVKG+9?'>IVBZDM_ING&51)%I[
MVS2!5/(#R;@<^N!Q6QX9UUM>TUY9[?[+>6TS6UW!G/ERKU`/<'((/H:S+G5M
M=US7+S2_#\MM96VG,([F^GB,I:4C.Q$R!P",D^M7]%;Q)!>S6>M"UNX`@>&_
MMQY>XYP4:,DX/?(XK,\63^+-'T_4M8L]5T\6MK&TL=O)9,S8`Z%M_P"N*T-#
MA\3&6*YU35;&YMI(MWE0V9C;)&1\Q<_RK,U'5]=G\7WVE6&K:=IT%I;PR@W4
M&]G+[LX^8=-OZUN:)!KD9D?5M3L[Z-U'E?9K8Q8]23N.:R]<U'7I/%UKHFCW
MEI:+)8O<O)<6YER5<+@88>M9>K>+==\&WT$.M-:ZQ'=Q.T8LH3%+&5*CE2S9
M4[NOK3-$NY/`MI<Z#KEE=M8^:[6=[:P/*CQ,>%;8"58?UJQX(TPIKU]J=C9W
M]EI#VZ0P1WTLA>5PQ+2!7)*C&!SUJ[X@2\T;Q5:^)K>RFOK7[*UG>16Z[I8U
MW;UD5?XL'(('.*H:WJY\<6B:#HMC>F&XE0WEY<6SPQP1JP8@;P"S'&`!6MXO
ML+XMI6LZ;;FZGTBX,IME.&FC92KA<_Q8.1]*S]3\9?VQID^F:#I6HSZC=1F$
M)/9O"D!88+2,P``&>V<UO6^E_P!E>#TTJ,F4VUCY(('+D)C]:YCPOXNATOPK
MIFG2Z+KDEW;6J1M$FFR<L!C`)`'XYK;\'Z;?6L6H:EJ<(M[O5;LW+6X;=Y*[
M0JJ2."<*,^YK%\5:#J%WXRLXK2%FT[6?*74F`.%$#;QGTW#Y?PI-8T"_E^(=
MO##"QTC47BO;Q@IVK)!G`/;YLQ_7;7?5S7P]MY[7P;:0W$,D,BR3$I(I5AF5
MB.#[51T[PTFJV?B2QU2VEBCN=7EFMY,;67Y4VR(?4$<'VIW@?3M<L=8U]M=`
M>:22!8[E5PMPJH5#CWP!D=C6=\;O^2?-_P!?<7]:U_AA_P`DXT;_`*XG_P!#
M:J^M^&[77OB#:G4M/>YLH]+<!SN""3S!@9!'.,\5M:3X1T#0[HW6FZ9#!.5V
M^;DLP'H"Q./PK/\`'FE_VO::1:-:O<P-JL!G1`3B/YLDXZ#WK(USP1I6AWVF
MZ[I.C?:$LIQ]JM`&EWHW'F*I)^9#@CVS75^)=).O^&K_`$M)/+:ZA*HY'"MU
M!/X@5B6OCDV=G'::KH>K1ZI$@1[>"S>596'&4<#:0?4D5>\&Z9?65C>WNIQ"
M"]U2\>[D@#9\D$`*F>Y"J,^]9J74_@O7M5>\L;NXTK4[C[7%=6L)E,,A4!T=
M5Y`XR#BM71O$%[KFINUOI4]MI,<?%S=HT4DTF?X$/.T#/)Q2^.+>:Z\$ZQ!;
MQ/--):.J1QJ69CCH`.M:]BK)86ZL"&$2@@]0<"N`URVTI/'VHW.N^'+K4[>6
MT@6WDCT]KA0PW[AD#CJ*ZKP_KEC?XL+'3-0LH[>(;!<63P(%'`"DC'X5D:[X
M<MM>^(-E_:6GO<V,>F2?.=P19/,7`W#'.,\5#9Z1IW@OQ7<M;Z-(UA?6JM'<
M10M,T,BMAHL\D*1M8>X:NYHHHHHHHHHHHHHHKSWXW?\`)/F_Z^XOZUK_``P_
MY)QHW_7$_P#H;5U=%%%%%%%%%%%%%%%%%%%%%%%%%%%%%>>_&[_DGS?]?<7]
<:U_AA_R3C1O^N)_]#:NKHHHHHHHHHHHHHHK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
